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Comprehensive investigation of nutritional health effects at the molecular level requires
the understanding of the interplay between three genomes, the food, the gut microbial,
and the human host genome. Food genomes are researched for discovery and exploitation
of macro- and micronutrients as well as speciﬁc bioactives, with those genes coding for
bioactive proteins and peptides being of central interest.The human gut microbiota encom-
passes a complex ecosystem in the intestine with profound impact on host metabolism. It
is being studied at genomic and, more recently, also at proteomic and metabonomic level.
Humans are being characterized at the level of genetic pre-disposition and inter-individual
variability in terms of (i) response to nutritional interventions and direction of health trajecto-
ries; (ii) epigenetic, metabolic programming at certain life stageswith health consequences
later in life and even for subsequent generations; and (iii) acute genomic expression as a
holistic response to diet,monitored at gene transcript, protein andmetabolite level.Modern
nutrition science explores health-related aspects of bioactive food components, thereby
promoting health, preventing, or delaying the onset of disease, optimizing performance
and assessing beneﬁts and risks in individuals and subpopulations. Personalized nutrition
means adapting food to individual needs, depending on the human host’s life stage, -style,
and -situation. Traditionally, nutrigenomics and nutri(epi)genetics are seen as the key sci-
ences to understand human variability in preferences and requirements for diet as well as
responses to nutrition.This article puts the three nutrition and health-relevant genomes into
perspective, namely the food, the gut microbial and the human host’s genome, and calls
for an “extended nutrigenomics” approach in order to build the future tools for personal-
ized nutrition, health maintenance, and disease prevention.We discuss examples of these
genomes, proteomes, transcriptomes, andmetabolomes under the deﬁnition of genomics
as the overarching term covering essentially all Omics rather than the sole study of DNA
and RNA.
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INTRODUCTION: NUTRITION, GENOMICS, AND HEALTH
Food, drinks, and water are the physical matter we adminis-
ter to our body, apart from the inhaled air and medical drugs.
Nutrition represents therefore the strongest life-long environmen-
tal impact on human health. Contemporary nutrition research
focuses on promoting health, preventing, or delaying the onset of
disease, optimizing performance, and assessing beneﬁts and risks
(Kussmann et al., 2006). These directions require comprehensive
strategies because: (a) food components interact with our body
not only at system, but also at organ, cell, and molecular level
(Kussmann and Daniel, 2008); and (b) nutritional improvement
of one health aspect should be accompanied by preservation of
health in all other respects (Kussmann and Fay, 2008).
Personalized nutrition means in practice adapting food to indi-
vidual needs. Those food products that address already require-
ments or preferences of speciﬁc consumer groups are typically
based on empirical research rather than molecular nutrition.
Nutrigenomics and nutrigenetics build the scientiﬁc framework
for understanding human genomic/genetic contributions to such
preferences, requirements, and responses to diet and may develop
into future means for consumers to assess their health and
nutritional status (Kussmann and Daniel, 2008).
This paper attempts to embrace the complexity of nutrige-
nomics research, which ultimately requires a metagenomic
approach, including the understanding of the interplay between
three genomes: the food, the host and – being located at the inter-
face – the gut microbial genome. We discuss examples of these
genomes, proteomes, transcriptomes, and metabolomes under the
deﬁnition of genomics as the overarching term covering essentially
all Omics rather than the sole study of DNA and RNA. The scope
of the article is depicted in Figure 1 that shows how for example
the plant genome affects the human genome either through direct
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FIGURE 1 | Extended nutrigenomics for nutrition and health: the plant genome for example affects the human genome either through direct impact of
its bioactives (incl. proteins and peptides), or indirectly via the gut microbial metabolism providing nutrients on which specific gut bacteria can feed.
impact of its bioactives (incl. proteins and peptides), or indirectly
via the gut microbial metabolism providing nutrients on which
speciﬁc gut bacteria can feed.
FOOD GENOMES ENCODE FOR BIOACTIVE PROTEINS AND
PEPTIDES
Besides carbohydrates and lipids, proteins represent one of the
three classes of macronutrients and are key actors in every cellu-
lar process. Enzymes are the proteins that catalyze virtually every
metabolic reaction, for example the digestive proteins pepsin and
(chymo)trypsin. Proteins also exhibit structural and mechani-
cal functions: the cytoskeleton maintains cell shape; actin and
myosin enable body motion. Moreover, proteins participate in cell
signaling and immune response.
Food proteins are differently composed due to their origin, i.e.,
animal or plant source. Hence, a balanced diet contains proteins
from different and complementary sources (e.g., meat, vegetables,
cereals, grains, legumes) to ensure a balanced amino acid supply.
The nutritional quality of proteins is assessed at the level of amino
acid composition, protein digestibility, and absorptive ability. The
body needs quite large amounts of protein in order to function
efﬁciently, also because proteins are continuously synthesized and
degraded, a phenomenon termed “protein turnover.”
Food proteomes are well characterized covering a broad range
of animal and plant protein sources (Fong et al., 2008; Gao
et al., 2009; Sakata et al., 2009). Beyond macronutrients, proteins,
and peptides are increasingly appreciated because of their variety
of bioactive components that exert functions as growth factors,
anti-hypertensive agents, antimicrobials, modiﬁers of food intake,
or immune regulators. Figure 2 summarizes some biological func-
tions and activities of bioactive peptides released from various
plant protein sources either by enzymatic digestion or through
processing/fermentation: again, the example of the plant world is
chosen with soy, rice, cereals, and sunﬂower as sources; through
enzymatic digestion or fermentation, bioactive peptides can be
released either in vitro (by processing) or in situ in vivo (upon
digestion) that can exert various beneﬁcial effects ranging from
protection against excessive oxidative stress and even cancer; via
cardiovascular to immune beneﬁts.
Biologically active motifs in polypeptide chains are fragments
that are inactive as long as they “reside” in their precursor
sequences, but upon release by proteolytic enzymes, they may
interactwith receptors and exert bioactivity (SchlimmeandMeisel,
1995; Meisel and Bockelmann, 1999). Bioactive peptides may be
released during the digestion by the host or microbial enzymes
(Grigorov and van Bladeren, 2007). They can also be gener-
ated during food processing (industrial processing) or ripening
(natural processing). In order to accurately address questions of
bioavailability and bioefﬁcacy, both systemically (i.e., in blood)
and locally (e.g., in the stomach and gut), bioactive peptides and
proteins should be identiﬁed and quantiﬁed all across from the
foodmatrix to the target tissues in the body. Bioactive peptides and
proteins have been discussed by Moller et al. (2008) and a database
of bioactive peptides has been established for classiﬁcation and
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FIGURE 2 | Functions of plant-derived bioactive peptides released
by enzymatic digestion or fermentation: again, the example of the
plant world is chosen with soy, rice, cereals, and sunflower as sources.
Through enzymatic digestion or fermentation, bioactive peptides can be
released either in vitro (by processing) or in situ in vivo (upon digestion)
that can exert various beneﬁcial effects ranging from protection against
excessive oxidative stress and even cancer; via cardiovascular to immune
beneﬁts.
potential bioactivity determination of food proteins (Minkiewicz
et al., 2008).
BIOACTIVE PEPTIDES FROM MILK AND DAIRY
Human breast milk is the nutrient source that has co-evolved
with humans to ideally support neonatal healthy growth and
development and to favor the maturation and maintenance of a
balanced immune system (Schack-Nielsen and Michaelsen, 2007).
Milk bioactives derive from its proteins and peptides (Severin
and Xia, 2005), lipids (German and Dillard, 2006), and oligosac-
charides (Ninonuevo et al., 2006) and these are present in var-
ious mammalian species. The protein content of human milk
can be split into caseins and whey with a 50:50 weight/weight
ratio, while bovine milk consists of 80% caseins and 20% whey
proteins (Severin and Xia, 2005). Caseins function as iron car-
riers and precursors of bioactive peptides, and whey proteins
exhibit critical functions in immune modulation and defense
(Madureira et al., 2007).Our research grouphas recently published
a review on Omics approaches to unravel the protein/peptide,
lipid, and carbohydrate content of human and animal milk
(Casado et al., 2009). We intentionally focus here on potential
and proven health-beneﬁcial bioactive milk peptides and pro-
teins. This said, dairy and other food proteins represent also a
source of potential or proven food allergens and can therefore
confer risks to susceptible consumers. We have discussed this
in other reviews with a different scope (Kussmann et al., 2005,
2006, 2010).
Human milk mainly is composed of caseins, α-lactalbumin,
lactoferrin, albumin, and various immunoglobulins and these
predominant proteins account for >99% of the milk protein
mass. The glycoprotein lactoferrin, an abundant mammalian
iron-binding milk whey protein (Lampreave et al., 1990),
profoundly inﬂuences the host defense system: it has been
demonstrated to prevent microbial growth, by direct interaction
between the protein and the Gram-negative bacterial membrane
(Farnaud and Evans, 2003); in addition, lactoferrin and peptides
derived from the full-length protein,have also been shown to inﬂu-
ence cytokine production in cell cultures, which mimic immune
and inﬂammatory actions of the body (Crouch et al., 1992).
Human colostrum (“ﬁrst milk”) has the highest concentration,
followed by human milk, then cow milk (150mg/L; Sanchez et al.,
1992).
However, the remaining<1% of the human milk protein com-
plement encompasses a complexmixture of bioactive proteins and
peptides, which is far from being completely characterized and
leveraged.
Human breast milk is the gold standard for neonate and
infant nutrition. Secretory immunoglobulins, lysozyme, inter-
feron, and growth factors, are known as immunological “assets”
of breast milk. Breast milk partly promotes the inhibition of bac-
terial pathogens and favors the growth of a protective colonic
microbiota (Levy, 1998). Apart from delivering basic nutrition
to the newborn, milk also protects the neonate and the mammary
gland against infection: breast-fed newborns experience normally
a lower incidence of gastro-intestinal infections and inﬂamma-
tory, respiratory, and allergic disorders. These beneﬁts have been
associated with diverse protective factors in breast milk. One such
speciﬁc biological activity in mother’s milk was reported as the
action of soluble CD14 (sCD14; Labeta et al., 2000; Vidal et al.,
2001): the study revealed a key role for sCD14 during bacterial
colonization of the gut and proposed sCD14 to be implicated in
modulating local innate and adaptive immune responses, thereby
controlling homeostasis in the neonatal intestine. Another related
study unraveled an interaction between soluble Toll-like receptor 2
(sTLR2) and sCD14 in plasma and milk, suggesting a novel innate
immune mechanism that may regulate microbially induced TLR
triggering (LeBouder et al., 2003).
Thepotential roles of food-derivedpeptides in reducing cardio-
vascular disease risk have been reviewed by Erdmann et al. (2008)
with respect to their beneﬁcial properties for blood pressure,
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oxidative stress, homeostasis, appetite, and lipid metabolism. The
beneﬁcial effects of lactotripeptides on hypertension have been
known for a long time: the tripeptidesVPP and IPP can inhibit the
angiotensin-converting enzyme (ACE) in vitro and are produced
by fermentation of milk by Lactobacillus helveticus and Saccha-
romyces cerevisiae; this fermented milk was then fed to rats and
resulted in lowered blood pressure (Masuda et al., 1996). Since that
time, several randomized controlled human trials have showed an
anti-hypertensive effect of VPP and IPP peptides derived from
milk: in Finnish and Japanese subjects with (mild) hyperten-
sion, systolic blood pressure was found reduced by ca. 5mmHg
during 4–12weeks of IPP+VPP supplementation (Geleijnse and
Engberink, 2010). The same suggested effect of these lactotripep-
tides on blood pressure has more recently been (re-)examined
in another six double-blind, placebo-controlled trials enrolling
a total of 780 subjects with either high to normal blood pres-
sure or untreated hypertension (UK and NL); intervention
periods lasted 4–8weeks, and IPP+VPP intake ranged from 2
to 10mg/day; in contrast to the earlier trials cited above, little
evidence for an anti-hypertensive effect of IPP+VPP and no
ACE inhibition was found in these latter studies (Geleijnse and
Engberink, 2010). Hence, while more recent data do not sup-
port a role for lactotripeptides in blood pressure regulation, one
cannot exclude a beneﬁcial effect in hypertensive subjects from
speciﬁc populations such as the Finnish and Japanese (Geleijnse
and Engberink, 2010).
The bioactivities of peptides “hidden” in major milk pro-
teins are latent until released and activated, e.g., by means of
food-technological treatment or during gastro-intestinal diges-
tion: bioactive peptides can be produced in vivo following intake
of milk proteins; and the proteolytic machinery of bacteria used in
fermentation (e.g., yogurt, cheese) can contribute to the release of
bioactive peptides or precursors thereof (Meisel, 2004). Autelitano
et al. (2006) coined the term“cryptome”to allude to the“dormant”
subset of peptides residing in the proteome; they promote the con-
cept that these cryptic peptides, or “crypteins,” with their various
bioactivities can be liberated from the parent protein via prote-
olytic cleavage. Proteomics is the obvious platform to study those
“cryptomes.”
BIOACTIVE PEPTIDES FROM SOY
There is a current trend toward ﬁnding alternative sources of high-
quality nutritious proteins either for reasons of economy (plants
are cheaper than meat); ecology and sustainability (producing
vegetable proteins is less resource demanding than for meat pro-
teins); or consumer preference (vegans or vegetarians). Hence, the
genomes of plant substitutes formeat protein including soy,wheat,
or legumes are increasingly explored for their general nutritional
value and content of speciﬁc bioactives.
Soybean is a geographically well established source of complete
food protein that supplies high amounts of all essential amino
acids. Its reported health beneﬁts are mainly attributed to its
isoﬂavones, saponins, proteins, and peptides (Erickson, 2005). The
bioactive compounds are typically not the soy proteins as such
but also the phytochemicals (Fang et al., 2004), and synergistic
effects between both have been suggested. Lunasin, Bowman-
Birk inhibitor, lectin, and beta-conglycinin are some of those
biologically active soy proteins and peptides (Park et al., 2005):
lunasin is a novel soy bioactive that can stop cancer cell division in
a skin cancer mouse model and inhibit core histone acetylation in
mammalian cells (de Lumen, 2005). Proteomic and metabolomic
responses to soy, e.g., isoﬂavones, polyphenolics, and carotenoids
were reviewed by Astle et al. (2007).
New approaches to more speciﬁcally separate and charac-
terize bioactive peptides in soy are emerging: Beermann et al.
(2009) investigated the anti-oxidative capacity of proteolytically
released peptides from soybean protein isolates. These ﬁndings
may open new nutritional applications because molecules with
free-radical scavenging capabilitiesmayprevent and treat oxidative
stress-related diseases.
BIOACTIVE PEPTIDE DISCOVERY – FROM CLASSICAL SCREENING TO
REVERSE-GENOME ENGINEERING
There are in silico and in vitro methods to discover and iden-
tify (new or known) bioactive peptides in food sources. The
classical in vitro approach starts with a functional fraction or
extract, potentially containing bioactives. These peptide mixtures
are typically tested in vitro, e.g., for their receptor-binding prop-
erties. Once an interesting fraction or extract has been identiﬁed,
it undergoes further fractionation and subsequent proteomic and
peptidomic analysis in order to narrow down and ultimately iden-
tify the active principle(s). The typically mass spectrometry-based
proteomic and peptidomic pipeline must be adapted to the com-
plexity and heterogeneity of full-length native bioactive peptides.
The latter differ from the typically tryptic peptides that are more
similar in size and in C-terminal terminal amino acids and are
generated for protein identiﬁcation in the biomarker business. We
have reviewed proteomic and peptidomic tools for the discovery
and characterization of bioactives and how these techniques differ
from the classical protein biomarker discovery (Panchaud et al.,
2008; Kussmann et al., 2010).
We and others increasingly follow another, complementary
and bioinformatics-driven strategy to discover and leverage bioac-
tive peptides (Figure 3): the approach has been coined “reverse-
genome engineering”and enables in silico discovery andprediction
of bioactive peptides (Grigorov and van Bladeren, 2007). First, the
public scientiﬁc domain can be searched for to date known bioac-
tive peptides and their (suggested) functions. These sequences can
then be mapped onto suitable food genomes in the plant or animal
world in order to unravel, where these peptides may be residing
in parent protein sequences (Figure 3). Three sequence map-
ping techniques can be deployed for this purpose: local similarity,
pattern, and motif/proﬁle searches with the latter two offering
greater sensitivity and speciﬁcity at the cost of slower speed. Local
similarity searches weight the amino acids in the to-be-searched
sequence equally, whereas the pattern search for example weights
the amino acid differently according to their position along the
sequence. In a further in silico analysis, either human digestive
or food processing-related conditions can be mimicked to reveal
the potential proteolytic release of the bioactive peptides from
their parent sequences (Figure 3). The result of this bioinformatic,
sequence-based approach is a set of known bioactive peptide
sequences found in and potentially released from food genomes,
which can then be followed up in vitro and in vivo. Evidently,
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FIGURE 3 |Workflow of bioinformatics-driven discovery of bioactive peptides. Blue: bioinformatics; green: peptidomics; orange: in vitro; purple: in vivo.
this top-down approach can signiﬁcantly reduce the number of
bioactivity tests to be performed and help ﬁlter the nutritionally
relevant and feasible candidates.
Ideally, one would like to expand from this literature
knowledge-dependent approach (based on peptides with reported
or suggested health beneﬁts) to peptide sequences in general, but
the prediction of bioactivity based on amino acid sequence alone
is not (yet) feasible.
GUT MICROBIAL GENOMES
Humans and other mammals are colonized by a complex, and
dynamic community of microorganisms. Adult humans are in
terms of cell numbers more prokaryotic than eukaryotic with 90%
of our cells estimated to be microbial, and only 10% human (Sav-
age, 1977). The impact of these indigenous microbial consortia
on human physiology is likely to be most important in the intes-
tine, because this organ harbors by far most of these bacteria. The
microbial densities in the proximal and middle small intestine
are relatively low but increase sharply in the distal small intestine
(∼108 bacteria/mL of luminal contents) and colon (1011–1012/g;
Savage, 1977). The microbiota in the adult human body encom-
passes a huge biomass of >100,000 billion bacteria spread over
>400 different species, which exhibit intense metabolic activity,
predominantly in the colon, and play an important physiological
role in the host (Bourlioux et al., 2003). Figure 4 shows where
food compounds (macro- and micronutrients) are digested and
absorbed in the gastro-intestinal tract (GIT) before theymay reach
various other body tissues. In theGIT, food stuffs interact with and
are partly metabolized by an enormous quantity and diversity of
bacteria residing in the stomach and, in particular, in the gut.
The gut microbes can be interpreted as a collective meta-
bolically active “organ” affecting the host’s energy metabolism
and immunity (Macpherson and Harris, 2004; Turnbaugh et al.,
2006). This concept has been championed by the groups of Gor-
don (Hooper et al., 2002; Backhed et al., 2005) and Nicholson
(Nicholson et al., 2005) and further pursued by ourselves (Rabot
et al., 2010). The microbiota can degrade a variety of dietary sub-
stances that are otherwise non-digestible and therefore inaccessible
to the host (Savage, 1986); one such example is the harvest of
energy from carbohydrates (Hooper et al., 2002). Colonization
of the gut by commensal bacteria has also been demonstrated to
inﬂuence the host’s intestinal physiology by modulation of genes
involved in nutrient absorption, gastro-intestinal and mucosal
immune function and xenobiotic metabolism (Hooper and Gor-
don, 2001; Hooper et al., 2001). One of the central functions of
the colonic microbiota is its capability to resist colonization by any
external new strain of bacteria (Bourlioux et al., 2003).
It is an enormous challenge to simulate the complex bacterial–
mucosal immune interaction deploying in vivo models. In one
such attempt, Nicholls et al. (2003) elucidated metabolic events
concomitant to acclimatization of germ-free (GF) rats to standard
laboratory conditions. In order to unravel gut microbial effects
under physiologically relevant conditions, animals with an a priori
sterile GIT and thenmono-colonizedwith probiotics are nowused
as a suitable model, especially the gnotobiotic mouse (Falk et al.,
1998; Hooper and Gordon, 2001; Hooper et al., 2001), but also GF
piglets (Danielsen et al., 2007). The latter model was recruited to
investigate how bacterial colonization affects the porcine intesti-
nal proteome (Danielsen et al., 2007): small-intestinal protein
expression patterns in gnotobiotic pigs maintained GF or mono-
associated with either Lactobacillus fermentum or non-pathogenic
Escherichia coli revealed that bacterial colonization differentially
affected proteolysis, epithelial proliferation and lipid metabolism,
which conﬁrms studies of other GF animal models.
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FIGURE 4 | Food compounds (macro- and micronutrients) are digested and absorbed the gastro-intestinal tract (GIT) before they may reach various
other body tissues. In the GIT, food stuffs interact with and are partly metabolized by an enormous quantity and diversity of bacteria residing in the stomach
and, in particular, in the gut.
Metabolomics is well suited and increasingly deployed to cap-
ture the metabolic interactions between the host metabolism and
the microorganisms of, e.g., the colonic microbiota (Nicholson
and Wilson, 2003). For example, metabolite proﬁling suggested
a contribution of gut microbiota to the fatty-liver phenotype
in insulin-resistant mice (Dumas et al., 2006): the relationship
between gut microbiota and host metabolism with regard to diet-
induced impaired glucose homeostasis and non-alcoholic fatty-
liver disease (NAFLD) in a mouse strain susceptible to these traits
was investigated by plasma and urine metabotyping; the genetic
pre-disposition of the mouse strain to impaired glucose home-
ostasis and NAFLD was correlated with disturbed choline metab-
olism,with some of the choline metabolites being co-processed by
symbiotic gut microbiota and mammalian enzyme systems.
Metabolomics also facilitated a correlation between the diver-
sity of the human metabolic phenotype and diet and blood pres-
sure, respectively (Holmes et al., 2008). Our research center has
compared GF mice colonized by a human baby ﬂora (HBF) or
a normal ﬂora to conventional mice at the level of microbiol-
ogy; metabolic proﬁling by 1H NMR of liver, plasma, urine, and
ileal ﬂushes; and by targeted analysis of bile acids and short-chain
fatty acids in the cecum (Martin et al., 2007). An association of
speciﬁcmetabotypeswith the residentmicrobiome became appar-
ent and revealed that the HBF has a remarkably simple micro-
biome/metabolome correlation network with a direct impact on
the host’s ability to metabolize lipids. Overall, this study pointed
out that the microbiome globally modulates absorption, storage,
and the energy harvest from the diet.
Along the same lines,our group investigated the probioticmod-
ulation of gut microbe–host interactions in a mouse model with a
humanized microbiome (Martin et al., 2008): metabolic effects of
exposure to either Lactobacillus paracasei or Lactobacillus rhamno-
sus were measured in HBF mice and generated a systems level view
of the host response to probiotic intervention. Probiotic exposure
led to microbiome modiﬁcation and resulted in altered hepatic
lipid metabolism accompanied by lowered plasma lipoprotein
levels and apparent stimulated glycolysis.
In another microbiota study related to digestive disorders,
our laboratory used a Trichinella spiralis-induced model of post-
infective IBS to investigate the effects of probiotics on gut dys-
function at metabolome level (Martin et al., 2006). The plasma
metabolic proﬁle of T. spiralis-infected mice showed elevated
energy metabolism and fat mobilization as well as a disruption
of amino acid metabolism due to increased protein breakdown,
which were related to the intestinal hypercontractility. Increased
concentrations of taurine, creatine, and glycerophosphorylcholine
in the jejunal muscles were associated with muscular hypertrophy
anddisrupted jejunal functions.L. paracasei treatment normalized
the muscular activity and the disturbed energy metabolism. Lastly,
altered levels of plasma metabolites (glutamine, lysine, methion-
ine) possibly related to modulated immunological responses were
also observed upon probiotic treatment.
The intestinal microbiota has also been investigated in the
context of the host’s energy metabolism. However, whether dif-
ferent gut microbial populations are a cause or a consequence
of for example deranged energy metabolism like in obese and
diabetic subjects remains to be proven. Recent studies showed
that GF mice are resistant to obesity when consuming a high-fat
(HF), high-carbohydrate diet, but it remains elusive which mech-
anisms are involved in the anti-obesity phenotype and whether
GF mice develop insulin resistance and dyslipidemia with HF
feeding. To shed more light on this, our research laboratories
compared the metabolic consequences of HF feeding on GF and
conventional mice (Rabot et al., 2010): GF mice consumed fewer
calories, excreted more fecal lipids, and weighed signiﬁcantly less
than conventional mice; GF/HF animals were both more insulin
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sensitive and glucose tolerant, showed reduced fasting and non-
fasting insulinemia, and had reduced plasma TNF-α and total
serum amyloid A levels. Reduced hypercholesterolemia, a mod-
erate accretion of hepatic cholesterol, and an increase in fecal
cholesterol excretion suggested an altered cholesterol metabolism
in GF/HF mice. Our results demonstrated that lower calorie input
and increased lipid excretion contributed to the obesity-resistant
phenotype of GF/HF mice and revealed that insulin sensitivity
and cholesterol metabolism are metabolic targets inﬂuenced by
the gut microbiota. Moreover and most importantly, data on
the link between the microbiota and obesity are also available
in humans: Turnbaugh et al. (2006) characterized an obesity-
associated gut microbiome with increased capacity for energy
harvest (Ley et al., 2006): two groups of beneﬁcial bacteria are
dominant in the human gut, the Bacteroidetes and the Firmicutes.
Ley et al. (2006) showed a relatively decreased proportion of Bac-
teroidetes in obese people compared to lean people and revealed
that this proportion increases with weight loss on two types of
low-calorie diet.
Ourmolecular understanding of howmembers of the intestinal
microbiota degrade complex polysaccharides derives from stud-
ies of Bacteroides thetaiotaomicron, an abundant component of
the normal human and mouse gut. Colonization of GF mice
with B. thetaiotaomicron (Btheta) has shown how this anaerobe
modiﬁes intestinal cellular differentiation and gene expression to
the mutual beneﬁt of both the host and the microbe (Bry et al.,
1996; Falk et al., 1998; Hooper et al., 2002). The Btheta proteome
encompasses speciﬁc functions for polysaccharide acquisition and
hydrolysis and a system that senses the environment (Sonnenburg
et al., 2005). Compared to the gut commensal andprobioticBtheta,
Biﬁdobacterium longum, a minor member but a commonly used
probiotic, has amore restricted glycan-degradationmachinery but
a larger repertoire of transporters (Hooper et al., 2002) suggest-
ing that B. longum may directly beneﬁt from Btheta’s “upstream”
polysaccharide degradation (Walker et al., 2006).
The gnotobiotic mouse model serves as a controlled situation
that enables the study of how a resident gut bacterium and a
probiotic species mutually adapt their substrate utilization. The
model furthermore shows the many dimensions and the speci-
ﬁcity of the relationship between the host, a generic component
of its microbiota, and intentionally consumed microbes such as
probiotics (Sonnenburg et al., 2006). The pioneering studies by
Gordon et al. demonstrate that gut ecology is extremely complex
and requires an ecosystem-levelmetagenomics approach to under-
stand the health impact of the intestinal microbiota and probiotics
(Falk et al., 1998; Xu and Gordon, 2003). Logically, nutrigenomics
has therefore been extended via metagenomics toward metapro-
teomics collecting information from all three proteomes: host,
food, and microbes. While techniques such as microarrays and
high-throughput sequencing (Huyghe et al., 2008; Hamady and
Knight, 2009) have delivered comprehensive data on the intesti-
nal bacterial population structure (Turnbaugh et al., 2009), more
recently the question has changed from “who is there?” to “who
is doing what?,” i.e., from a population census (Turnbaugh and
Gordon, 2009) to an activity proﬁling, the latter being facilitated
by metaproteomic analyses (VerBerkmoes et al., 2009). The lat-
ter approach adds the proteomics-typical additional challenge
of any (meta)proteome being much more complex than any
(meta)genome.
The ﬁeld of gut microbial ecology has provided a few ﬁrst
examples of trans-genomic interaction studies investigating cross-
talk between intestinal microbiota and the human host via the
host/guest metabolism. These studies do not necessarily take a
whole-genome approach but nevertheless embark in principle
on the interaction of the three “Omes,” namely the intestinal
metabolome, the host’s genome and the microbiome. Biagi et al.
(2011) for example delivered a metagenomic perspective of the
aging process in the human gut: they introduce human beings as
“meta-organisms” with a more holistic view of the aging process
and the interaction between environment, intestinal microbiota
and host taken into consideration. Age-related physiological
changes of theGIT, the lifestyle,nutritional behavior, and the host’s
immune system affect the gut microbial ecosystem. Biagi et al.
(2011) review the current knowledge of gut microbial changes in
aging people and propose age-related gut microbial unbalances
to be involved in “inﬂamm-aging” and immunosenescence. In
view of the importance of gut microbiota homeostasis for host
health they consider medical and nutritional applications based
on probiotic and prebiotic preparations speciﬁc for the elderly.
They also review the few clinical intervention trials reporting the
use of pre-/probiotics in the elderly.
Ng et al. (2010) investigated the relationship between human
intestinal dendritic cells (DCs), gut microbiota, and Crohn’s dis-
ease (CD) activity. They found that intestinal DC IL-6 production
is increased in CD patients and correlated with disease activity and
C-reactive protein (CRP). In terms of host–microbe interaction,
they suggest that bacterially driven local IL-6 production by host
intestinal DC may result in unopposed effector function and tis-
sue damage. This would mean that intestinal DC function can be
inﬂuenced by the commensal microbiota composition.
Pruteanu et al. (2011) studied the degradation of the extra-
cellular matrix components by bacterial-derived metalloproteases
and possible implications for inﬂammatory bowel disease (IBD).
Proteolytic degradation of the extracellular matrix is a hall-
mark of mucosal homeostasis and tissue renewal, but also con-
tributes to complications of intestinal inﬂammation. It is not
known, whether this is entirely host-derived, or, in part, exhib-
ited by the gut microbiota. Therefore, Pruteanu et al. (2011)
screened fecal bacterial colonies from 20 healthy controls, 23
subjects with ulcerative colitis (UC), and 18 CD patients for
gelatinolytic activity. Metalloprotease genes were detected by PCR.
The physiological signiﬁcance and potential implications of such
microbe-driven matrix degradation were conﬁrmed by reduced
transepithelial resistance (TER) after exposure of rat distal colon
to culture supernatants of C. perfringens. The group concluded
that microbial proteolytic activity has the capacity to contribute
to mucosal homeostasis and may participate in the pathogenesis
of IBD.
THE HUMAN GENOME
Healthy adult humans vary considerably in their appearance,phys-
ical, and cognitive performance and also in their food preferences
and requirements. Nutrition science has recognized that different
life situations and phases require adequately adapted food intake:
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so do pregnant women, active athletes, and elderly people have
very distinct and speciﬁc dietary requirements. Individual food
choices and personalized solutions have a long history of being
a consequence of preference, culture, life stage; and also, as more
recently discovered, life style, disease, and genetics.
GENETICS TO CLARIFY PRE-DISPOSITION TO DIET AND HEALTH
Nutrigenetics investigates the genetic pre-disposition of an
individual with regard to its response to diet. Single-nucleotide
polymorphisms (SNPs) are single-base mutations in genes and
are considered today as the most common and important inter-
individual genetic differences at gene sequence level (Zhao et al.,
2004). This said, also other genetic modiﬁcations such as dele-
tions (Smith et al., 2008), insertions (Payton et al., 2005) and copy
number variants (CNVs;Need et al., 2009), are important and con-
tribute to inter-individual variability in humans. SNPs can occur
in both exons and introns, i.e., in coding and non-coding DNA
regions, and some have important functional consequences (Nel-
son et al., 2004). We believe that hypothesis-driven approaches to
assess variants of speciﬁc, metabolically relevant genes in subjects
enrolled in nutritional interventions can improve study design
and readout. One such promising scenario is based on probing
genetic variants in G-proteins (heterotrimeric guanine – binding
proteins), for the following reasons:
G-proteins are expressed in all cells of the human body. Their
main function is to translate signals from the cell surface into
a cellular response (Bourne, 1997). They represent a signaling
funnel of some 30 proteins, positioned between thousands of
extracellular signals, hundreds of membrane receptors and again
thousands of intracellular effector molecules. G-proteins are het-
erotrimers and consist of α-, β-, and γ -subunits encoded by
different genes (Downes andGautam,1999). Thisα-,β-,γ-subunit
composition determines their receptor and effector speciﬁcity
(Gautam et al., 1998). Given the crucial role of G-proteins in vir-
tually all intracellular signal transduction processes, it has been
shown that mutations altering the expression or structure of
these proteins can contribute to or even cause health disorders
(Siffert, 2005).
Metabolically relevant SNPs in G-proteins have been exten-
sively characterized (Gutersohn et al., 2000; Wenzel et al., 2002;
Hauner et al., 2003; Nurnberger et al., 2003; Holtmann et al., 2004;
Siffert, 2005; Mitchell et al., 2006; Frey et al., 2008). G protein
gene variants have been shown to directly impact weight regu-
lation (Gutersohn et al., 2000; Hauner et al., 2003; Frey et al.,
2008): Hauner et al., 2003 genotyped 111 participants of a ran-
domized placebo-controlled clinical trial for the GNB3 C825T
polymorphism and analyzed associations of genotypes with out-
come of a structured weight loss program with administration of
either placebo or 15mg Sibutramine daily for 54weeks; the C825T
polymorphism in the β3-subunit encoded by the gene GNB3
could predict whether a weight reduction under Sibutramine ther-
apy would be successful or not. A similar observation has been
made for the GNAS gene that mediates cAMP increase in sev-
eral cell types after hormonal stimulation. The GNAS G(-1211) A
genotype, too, inﬂuences the individual response to Sibutramine-
induced weight loss intervention. Lastly, the GNA11 G(-659)C
genotype in the G protein Ga11 has also a strong inﬂuence on the
Sibutramine intervention (Frey et al., 2008). Taken together these
results suggest that G protein-directed genotyping may render
nutritional intervention more speciﬁc and powerful.
Most G protein studies in Caucasian populations reveal a pos-
itive association between 825T allele carrier status in the GNB3
subunit gene on the one hand and increased risk for hypertension
on the other hand (Nurnberger et al., 2003). This has been shown
in particular for large populations genotyped within a German
(Siffert, 2005) and Belgian study. Moreover, evidence emerges that
the 825T allele frequency is increased in hypertensive patients with
typical features of the metabolic syndrome (Siffert, 2005): young,
lean, normotensive male 825T allele carriers already reveal ﬁrst
signs of themetabolic syndrome, such as increased total cholesterol
and uric acid concentration, but not yet insulin resistance (sim-
ilar metabolic derangements were found in older Europeans and
Japanese; Siffert, 2005). In older hypertensive subjects possessing
the TT or TC genotype of GNB3, insulin resistance seems to
be more frequent than in CC genotype individuals. Overall, the
studies discussed above raise the question whether hypertension
associated with the C825T polymorphism may be just one facet
of the metabolic syndrome. The 825T association with increased
risk for type 2 diabetes mellitus (T2DM) remains to be proved
(Siffert, 2005).
In view of the evidence outlined above, genotyping healthy
adult volunteers enrolled in weight management trials at the G
protein level appears promising and complementary to probing
othermetabolically relevant genes for subject characterization and
cohort stratiﬁcation.
A more medical and disease-preventive nutrigenetic context
is given by the genetic basis of neural tube defects (NTD),
cancer and their correlation with folate and methionine metab-
olism: a C→T substitution in the gene encoding methylene-
tetrahydrofolate-reductase (MTHFR), the enzyme that produces
5-methyl-tetrahydrofolate (5-methyl-THF) required for the con-
version of homocysteine to methionine, is quite common. Indi-
viduals with the T/T genotype display functionalmetabolic effects,
e.g., changes in one-carbon folate derivatives, elevated plasma
homocysteine and different response to folic acid supplementa-
tion compared with normal (C/C) or heterozygous (C/T) geno-
types. These metabolic changes associated with the T/T genotype
can modify risk for chronic disease (e.g., vascular disease and
cancer) and NTD if they coincide with folate deﬁciency (Bailey
and Gregory III, 1999). Bailey and Gregory III (1999) discussed
MTHFR polymorphisms in terms of metabolic signiﬁcance, risk,
and impact on folate requirement. From the observed modula-
tion of these metabolic deviations by increasing folate intake they
conclude that folate requirements may be different in affected
individuals (T/T) relative to normal (C/C) or heterozygous (C/T)
individuals.
Effective folate supplementation prevents NTD occurrence.
Together with the high blood homocysteine levels in NTD
children’s mothers, this suggests folate genes [methylene-
tetrahydrofolate-reductase (MTHFR) and -dehydrogenase
(MTHFD)] and homocysteine metabolism genes (methionine
synthase; methionine synthase reductase; cystathionine syn-
thase) to be involved in NTD etiology. Gos Jr. and Szpecht-
Potocka, 2002 reviewed this topic and presented a list of folate
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and homocysteine metabolism genes known to be involved
in NTD with an emphasis on primary and secondary NTD
prevention.
EPIGENETICS TO UNDERSTAND METABOLIC PROGRAMMING
Epigenetics means“above the genetics”and alludes to mechanisms
that control gene expression without changing the DNA sequence.
Epigenetic changes encompass molecular modiﬁcations to both
DNA and chromatin (Klose and Bird, 2006; Talbert and Henikoff,
2006). DNA methylation and changes to chromatin packaging
of DNA by post-translational modiﬁcations of histone proteins
are the most extensively investigated mechanisms (Klose and
Bird, 2006; Talbert and Henikoff, 2006). Other epigenetic events
include regulation by non-coding RNAs, such as microRNAs,
and mechanisms that control the higher-level organization of
chromatin within the nucleus (Jirtle and Skinner, 2007). Apart
from the relevance for environmental programming, epigenetic
mechanisms are ﬁrst and foremost central elements of devel-
opment and differentiation: epigenetic regulation is involved
in tissue-speciﬁc gene expression and silencing (Slotkin and
Martienssen, 2007).
Epigenetics provides a biochemical framework for long-term
effects of environmental experiences, metabolic programming
and adaptive development (Jirtle and Skinner, 2007). Epigenetic
changes happenmost commonly during gestation,neonatal devel-
opment, puberty, and old age. During early embryogenesis, the
mammalian genome is “cleaned” of most epigenetic marks, with
the latter then being progressively re-established during embry-
onic development (Gluckman et al., 2009). The epigenome is
therefore environmentally most vulnerable during embryogene-
sis. Epigenetic marks may be inherited from one generation to the
next, either directly by preservation through meiosis or, indirectly
in the next generation, through replication of the conditions, in
which the epigenetic change occurred in the ﬁrst place (Gluckman
et al., 2009). These observations pile up to substantial evidence for
the developmental origins of health and disease with underlying
epigenetic mechanisms (Gluckman et al., 2009).
Characterizing the expression proﬁles of epigenetically con-
trolled genes should reveal early biomarkers for disease, exposure,
intervention, and efﬁcacy. In a second phase, these markers should
translate into early diagnosis of individuals with a propensity for
adult-onset disease and may ultimately deliver novel therapeutic
approaches that prevent and treat diseases before classical symp-
toms become visible. This contrasts with current human disease
management, which typically aims at treating and curing dis-
ease after its onset. In this regard, epigenetics can be expected
to play a key role in nutrition: modern nutrition research focuses
on disease prevention and health preservation. Ultimately, com-
prehensive knowledge of the human epigenome will be required,
as the epigenome is not only tissue and stage-of-life dependent,
but also varies markedly between individuals and species.
Current mechanistic evidence for environmental epigenetic
programming, by nutritional or other routes, has been mainly
generated in animal studies. But also human epidemiol-
ogy increasingly highlights associations between environmental
impact – especially prenatal and early postnatal – and long-
term epigenetic modiﬁcations manifesting in health and disease
phenotypes (Yajnik, 2004; Painter et al., 2005). Developmental
plasticity generally manifests when environmental exposure pro-
duces a broad range of adult phenotypes from a single genotype by
epigenetically altering gene expression (Boney et al., 2005; Sing-
hal, 2006); but developmental plasticity does not only allow an
organism to adapt to environmental signals during early life; it
can also increase the risk of chronic diseases, namely in the case of
a mismatch between the early perceived environment and the one
encountered later in adulthood.
Developing organisms appear to be particularly susceptible to
epigenetic changes. The effects of suboptimal nutrition during
the peri-conceptional period shows the “epigenetic sensitivity” of
this developmental phase (Sinclair et al., 2007; Heijmans et al.,
2008), in which widespread re-programming of the epigenome
occurs (Nafee et al., 2008). But also nutritional constraints later
in pregnancy (Vickers et al., 2000; Painter et al., 2005), postnatal
over-nutrition leading to rapid growth (Vickers et al., 2000;
Singhal, 2006), and maternal–fetal over-nutrition (Schaefer-Graf
et al., 2005) can cause metabolic deregulation later in life. For
each of these situations, epigenetic changes have been reported
(Waterland et al., 2006; Gluckman et al., 2007; Aagaard-Tillery
et al., 2008). The importance of the peri-conceptional period,
when suboptimal nutrition can have long-lasting effects with-
out affecting birth weight (Painter et al., 2005; Heijmans et al.,
2008), underscores the need for healthy nutrition during the
pre-pregnancy period, when nutrition may often be unbalanced,
even for women in wealthy countries (Robinson et al., 2004). So
does the related ﬁnding of (im)balanced intake of micronutrients
involved in one-carbon metabolism during pregnancy affecting
the subsequent metabolic health of the offspring (Yajnik et al.,
2008) have implications for nutritional supplementation.Research
in animal models went beyond analysis and has demonstrated
that such adverse effects of impaired early life nutrition and the
associated epigenetic changes can be even prevented (Lillycrop
et al., 2005) or reversed (Vickers et al., 2005; Gluckman et al.,
2007) by nutritional interventions (such as folate supplementa-
tion) or endocrinological interventions (such as neonatal leptin
administration).
In our view, epigenetics in nutrition should play an impor-
tant role in investigating mechanistic underpinnings of long-term
human health effects of nutrients, ingredients and, possibly, entire
diets. In more fundamental studies relying on animal models,
the epigenetic dimension of, e.g., nutritionally promoting lean
body mass and of dietary mimicking the life-prolonging effects of
caloric restriction could be explored.
CONCLUSION
The food genomes interactwith the human genome, either directly
ormediated by the interfacing gutmicrobialmetagenome. Polyun-
saturated fatty acids for example directly bind to particular tran-
scription factors (such as PPARs) that in turn switch on a gene
expression machinery – a most direct interaction between a food
component and the host genome. On the other hand, human
milk-derived oligosaccharides favor the colonization of the infant
gut by health-beneﬁcial bacteria that in turn impact the host’s
metabolism – an indirect, but powerful gut microbiota-mediated
interaction between a food compound class and the host genome
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resulting in a symbiotic relationship between food stuff and
intestinal bacteria.
This perspective and these examples illustrate that we need to
understand the regulation and variability of the human genome
as a response to its exposure to the food genomes (f. ex. bioactive
dairy peptides) in conjunction with the host’s gut microbiome:
– Functional food with added health value starts with a holistic,
genomic perspective of how we can leverage the richness of
bioactives derived from food sources, with milk-derived bioac-
tive peptides being a prominent example – this refers to the
bioinformatic and proteomic exploitation of the food genomes.
– Then we need to see where, when, and how these bioactives
interact with the human body, either directly, or metabolized by
either the host or the gut microbiome, and how these interac-
tions translate into physiological consequences – this refers to
the Omics-level elucidation of nutritional health effects.
– As an important dimension of this food–host interaction,
we need to take the human gut microbiome as a metabolic
organ into account, a perspective which ultimately requires a
metagenomic approach.
– In a further step, the inter-individual differences in human
responses to diet should be understood – this can be partly
addressed through genotyping for metabolically relevant genes.
– We should monitor long-term health consequences of (early)
nutrition and try to understand, in which tissues and at which
molecular level these effects may be mediated by epigenetic
mechanisms.
Whereas gene and protein expression studies as well as metabo-
lite proﬁling in humans investigating (rather acute) responses to
nutritional interventions have become standard for mechanistic
nutritional research (and are reviewed elsewhere by us and others),
both validation and translation of the results are still challenging.
There are emerging examples of functionally impacting polymor-
phisms in metabolically relevant genes that determine whether or
not, or to which extent an individual beneﬁts from a speciﬁc diet
or ingredient. However, nutrigenetics-based foods are still to be
developed. Finally, we are only at the beginning to appreciate how
epigenetic programming is not only a natural part of develop-
ment and differentiation but also a mechanism of long-term gene
expression changes that result in “metabolic memory.”
In our view, current and future molecular food research should
ask precise nutritional questions; answer them in highly deﬁned
and controlled studies all across fromwell-deﬁned diets and ingre-
dients to standardized genomic readouts; and, most importantly,
assess the outcomes with a multitude of holistic genomic and
genetic tools, combined with extensive phenotyping.
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